Alan Skarbnik, MD

Dr. Alan Skarbnik, Director of the CLL and lymphoma program at Novant Health, brings his expertise in follicular lymphoma to the table. He discusses patient-centered care, emphasizing the importance of tailoring therapies to individual preferences. The conversation dives into the treatment landscape, including innovative bispecific antibodies and CAR-T therapies, and addresses the challenges of managing relapses. Skarbnik also highlights the need for personalized strategies in the evolving field of molecular therapies, ensuring patients receive the most effective and compassionate care.

Alan Skarbnik, MD, and Manni Mohyuddin, MBBS, discuss measurable residual disease (MRD) in blood cancers, highlighting controversies, implications of MRD negativity, harmonizing MRD thresholds, and testing MRD technology in trials. They explore the challenges in achieving and maintaining MRD negativity for long-term disease control, individualized approaches based on disease specifics, and the importance of overall survival benefits in chronic diseases like CLL.